Nanoparticle T cell engagers for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%. The standard-of-care for AML has not changed in the past few decades. Promising immunotherapy options are being developed for the treatment of AML; yet, these regimens require highly laborious and...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhallak, Kinan, Sun, Jennifer, Muz, Barbara, Jeske, Amanda, Yavner, Jessica, Bash, Hannah, Park, Chaelee, Lubben, Berit, Adebayo, Ola, Achilefu, Samuel, DiPersio, John F., Azab, Abdel Kareem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448516/
https://www.ncbi.nlm.nih.gov/pubmed/34548905
http://dx.doi.org/10.18632/oncotarget.28054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448516/
https://www.ncbi.nlm.nih.gov/pubmed/34548905
http://dx.doi.org/10.18632/oncotarget.28054

Ejemplares similares